What effects does pioglitazone have on stroke risk for patients with insulin resistance?
Pioglitazone has been shown to reduce the risk of recurrent stroke or 11.8% among placebo recipients to 9.0% among pioglitazone recipients in the IRIS trial. However, active treatment was associated with weight gain and increased bone fracture risk, which have restrained its clinical use.